BioInvent International AB (publ) BOVNF
0.44 USD -0.17 (-27.16%)
At closeNov 2, 2026, 4:00 PM EST
0.3995 Day range 0.3995
0.3995 52-week range 3.29
- YTD
- -86.50%
- 1 year
- -86.50%
News
seekingalpha.com BioInvent International AB (publ) (BOVNF) Q3 2026 Earnings Call Transcript BioInvent International AB (publ) (BOVNF) Q3 2026 Earnings Call Transcript
accessnewswire.com BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026 BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian…
accessnewswire.com BioInvent International AB Announces that its CFO will Retire in 2027 LUND, SE / ACCESS Newswire / October 12, 2026 / BioInvent International AB ("BioInvent") (STO:BINV) , a leader in the discovery of novel immunomodulatory antibodies, today announced that the…
seekingalpha.com BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
accessnewswire.com BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026 LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it…
accessnewswire.com Resolutions at BioInvent's Annual General Meeting 2026 LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as…
accessnewswire.com BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio Events will feature expert perspectives on BI-1808 in ovarian cancer and T‑cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International…
accessnewswire.com BioInvent International AB: Interim Report January - March 2026 LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most…
accessnewswire.com BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when…
accessnewswire.com BioInvent International AB Publishes Annual Report 2025 LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class…
accessnewswire.com Notice to Annual General Meeting in BioInvent International AB LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual…
seekingalpha.com BioInvent International AB (publ) (BOVNF) Q4 2025 Earnings Call Transcript BioInvent International AB (publ) (BOVNF) Q4 2025 Earnings Call Transcript
accessnewswire.com BioInvent International AB: Year-End Report January 1 - December 31, 2025 LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets,…